Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients

This study tests whether continuing somatostatin analogues (long-acting hormone-blocking injections used to slow neuroendocrine tumor growth) alongside second-line treatments like everolimus, sunitinib, or PRRT (a targeted radiation therapy) improves outcomes compared to stopping them at disease progression. **You may be eligible if...** - You are 18 or older with a histologically confirmed, slow-growing neuroendocrine tumor of the gastrointestinal or pancreatic type (GEP-NET, grade 1 or 2) - Your tumor is locally advanced or has spread, and it has progressed on first-line somatostatin analogue treatment - You are about to start second-line therapy with everolimus, sunitinib, or PRRT with lutetium **You may NOT be eligible if...** - Your doctor recommends chemotherapy as second-line treatment for your NET - You have a poorly differentiated (high-grade) neuroendocrine carcinoma - You have severe organ dysfunction Talk to your doctor to see if this trial is right for you.